Onodera M - Search Results

1

Potent vaccine therapy with dendritic cells genetically modified by the gene-silencing-resistant retroviral vector GCDNsap.

Nabekura T, Otsu M, Nagasawa T, Nakauchi H, Onodera M. Nabekura T, et al. Among authors: onodera m. Mol Ther. 2006 Feb;13(2):301-9. doi: 10.1016/j.ymthe.2005.09.021. Epub 2005 Nov 28. Mol Ther. 2006. PMID: 16311073 Free article.

2

Stable transgene expression in mice generated from retrovirally transduced embryonic stem cells.

Hamanaka S, Nabekura T, Otsu M, Yoshida H, Nagata M, Usui J, Takahashi S, Nagasawa T, Nakauchi H, Onodera M. Hamanaka S, et al. Among authors: onodera m. Mol Ther. 2007 Mar;15(3):560-5. doi: 10.1038/sj.mt.6300063. Epub 2006 Dec 19. Mol Ther. 2007. PMID: 17180117 Free article.

3

An immunotherapy approach with dendritic cells genetically modified to express the tumor-associated antigen, HER2.

Nabekura T, Nagasawa T, Nakauchi H, Onodera M. Nabekura T, et al. Among authors: onodera m. Cancer Immunol Immunother. 2008 May;57(5):611-22. doi: 10.1007/s00262-007-0399-8. Epub 2007 Sep 5. Cancer Immunol Immunother. 2008. PMID: 17786440 Free PMC article.

4

A new red fluorescent protein that allows efficient marking of murine hematopoietic stem cells.

Sanuki S, Hamanaka S, Kaneko S, Otsu M, Karasawa S, Miyawaki A, Nakauchi H, Nagasawa T, Onodera M. Sanuki S, et al. Among authors: onodera m. J Gene Med. 2008 Sep;10(9):965-71. doi: 10.1002/jgm.1232. J Gene Med. 2008. PMID: 18613301

5

Simplified retroviral vector gcsap with murine stem cell virus long terminal repeat allows high and continued expression of enhanced green fluorescent protein by human hematopoietic progenitors engrafted in nonobese diabetic/severe combined immunodeficient mice.

Kaneko S, Onodera M, Fujiki Y, Nagasawa T, Nakauchi H. Kaneko S, et al. Among authors: onodera m. Hum Gene Ther. 2001 Jan 1;12(1):35-44. doi: 10.1089/104303401450942. Hum Gene Ther. 2001. PMID: 11177540

6

An in vivo assay for retrovirally transduced human peripheral T lymphocytes using nonobese diabetic/severe combined immunodeficiency mice.

Kaneko S, Nagasawa T, Nakauchi H, Onodera M. Kaneko S, et al. Among authors: onodera m. Exp Hematol. 2005 Jan;33(1):35-41. doi: 10.1016/j.exphem.2004.10.006. Exp Hematol. 2005. PMID: 15661396 Free article.

7

[Gene therapy for leukemia].

Kaneko S, Onodera M, Nagasawa T. Kaneko S, et al. Among authors: onodera m. Nihon Rinsho. 2005 Dec;63 Suppl 12:637-40. Nihon Rinsho. 2005. PMID: 16416866 Review. Japanese. No abstract available.

8

The induction of tumor-specific CD4+ T cells via major histocompatibility complex class II is required to gain optimal anti-tumor immunity against B16 melanoma cell line in tumor immunotherapy using dendritic cells.

Fujisawa Y, Nabekura T, Nakao T, Nakamura Y, Takahashi T, Kawachi Y, Otsuka F, Onodera M. Fujisawa Y, et al. Among authors: onodera m. Exp Dermatol. 2009 Apr;18(4):396-403. doi: 10.1111/j.1600-0625.2008.00802.x. Epub 2008 Oct 23. Exp Dermatol. 2009. PMID: 19054057

9

Enforced ROR(gamma)t expression in haematopoietic stem cells increases regulatory T cell number, which reduces immunoreactivity and attenuates hypersensitivity in vivo.

Fujisawa Y, Nabekura T, Kawachi Y, Otsuka F, Onodera M. Fujisawa Y, et al. Among authors: onodera m. Asian Pac J Allergy Immunol. 2011 Mar;29(1):86-93. Asian Pac J Allergy Immunol. 2011. PMID: 21560493 Free article.

10

Gene transduction of tristetraprolin or its active domain reduces TNF-alpha production by Jurkat T cells.

Suzuki E, Tsutsumi A, Goto D, Matsumoto I, Ito S, Otsu M, Onodera M, Takahashi S, Sato Y, Sumida T. Suzuki E, et al. Among authors: onodera m. Int J Mol Med. 2006 May;17(5):801-9. Int J Mol Med. 2006. PMID: 16596264

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

472 results

Search Page